2022
Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
Tuan J, Kayani J, Fisher A, Kotansky B, Dembry L, Datta R. Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e83. PMID: 36483361, PMCID: PMC9726471, DOI: 10.1017/ash.2022.229.Peer-Reviewed Original ResearchDalbavancin administrationOutpatient parenteral antimicrobial therapyDose of dalbavancinMedian antibiotic durationSoft tissue infectionsParenteral antimicrobial therapyAntibiotic durationDeveloped hepatotoxicityClinical cureSeptic arthritisClinical outcomesAntimicrobial therapyPatientsAdministrationDaysEndocarditisArthritisBacteremiaOsteomyelitisHepatotoxicityTherapyDalbavancinInfectionDose
2018
Long-Acting Lipoglycopeptides for Gram-Positive Bacteremia at the End of Life to Facilitate Hospice Care: A Report of 3 Cases
Datta R, McManus D, Topal J, Juthani-Mehta M. Long-Acting Lipoglycopeptides for Gram-Positive Bacteremia at the End of Life to Facilitate Hospice Care: A Report of 3 Cases. Open Forum Infectious Diseases 2018, 5: ofx277. PMID: 29399598, PMCID: PMC5788065, DOI: 10.1093/ofid/ofx277.Peer-Reviewed Original Research
2010
Risk of Postdischarge Infection with Vancomycin-Resistant Enterococcus after Initial Infection or Colonization
Datta R, Huang SS. Risk of Postdischarge Infection with Vancomycin-Resistant Enterococcus after Initial Infection or Colonization. Infection Control And Hospital Epidemiology 2010, 31: 1290-1293. PMID: 20979493, PMCID: PMC3075426, DOI: 10.1086/657332.Peer-Reviewed Original Research